Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rayne H Rouce

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Blood Advances|February 5, 2025
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomasYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapyYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Blood Advances|May 3, 2024
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J Lamble, Liora M Schultz, Khanh Nguyen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2018
CD7 CAR T Cells for the Therapy of Acute Myeloid LeukemiaDiogo Gomes-Silva, Erden Atilla, Pinar Ataca Atilla, et al.
Transplantation and Cellular Therapy|November 1, 2025
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental GroupCandelaria Deimundo Roura, Persis Amrolia, Marc Ansari, et al.
Cell Reports. Medicine|July 10, 2024
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityRoyce Ma, Mae Woods, Phillip Burkhardt, et al.
Blood Advances|November 21, 2024
American Society of Hematology: building a comprehensive minority recruitment and retention professional programMargo R Rollins, Rahma M Warsame, Melody Smith, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Cytotherapy|May 31, 2024
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsAnne Miller, Rachel Daum, Tao Wang, et al.
Pediatric Blood & Cancer|January 20, 2025
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid TumorsAaron B Ross, Kriti Puri, Thomas L Johnson, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Blood Advances|February 5, 2025
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomasYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapyYomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, et al.
Blood Advances|May 3, 2024
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J Lamble, Liora M Schultz, Khanh Nguyen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2018
CD7 CAR T Cells for the Therapy of Acute Myeloid LeukemiaDiogo Gomes-Silva, Erden Atilla, Pinar Ataca Atilla, et al.
Transplantation and Cellular Therapy|November 1, 2025
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental GroupCandelaria Deimundo Roura, Persis Amrolia, Marc Ansari, et al.
Cell Reports. Medicine|July 10, 2024
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityRoyce Ma, Mae Woods, Phillip Burkhardt, et al.
Blood Advances|November 21, 2024
American Society of Hematology: building a comprehensive minority recruitment and retention professional programMargo R Rollins, Rahma M Warsame, Melody Smith, et al.
Transplantation and Cellular Therapy|May 18, 2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell TherapiesRebecca A Gardner, Claire White, Magdi Elsallab, et al.
Cytotherapy|May 31, 2024
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumorsAnne Miller, Rachel Daum, Tao Wang, et al.
Pediatric Blood & Cancer|January 20, 2025
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid TumorsAaron B Ross, Kriti Puri, Thomas L Johnson, et al.
Pageof 6